Disease · MONDO_0005859

mucocutaneous leishmaniasis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. mucocutaneous leishmaniasis. Diseases, record MONDO_0005859. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005859

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: mucocutaneous leishmaniasis; Open Targets
Open Targets ID: MONDO_0005859; Open Targets
Other names: American cutaneous leishmaniasis, American mucocutaneous leishmaniasis, American mucocutaneous leishmaniasis (disorder), Leishmaniasis, Mucocutaneous, Mucocutaneous leishmaniasis, American, New World cutaneous leishmaniasis, cutaneous leishmaniasis, American; Open Targets
Disease Ontology: DOID:9155; Disease Ontology
MeSH: D007897; MeSH
NCI Thesaurus: C34769; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 6 drugs, from DailyMed; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MILTEFOSINE	CHEMBL125	Small molecule	Approval	DailyMed	6	5	5	Drugs and targets
AMPHOTERICIN B	CHEMBL267345	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ANTIMONY	CHEMBL4297652	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MEGLUMINE ANTIMONATE	CHEMBL239129	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
SODIUM STIBOGLUCONATE	CHEMBL6067962	Small molecule	Unknown	ClinicalTrials.gov	2	2	2	Drugs and targets
ALLOPURINOL	CHEMBL1467	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
XDH	Xanthine dehydrogenase/oxidase	1	Xanthine dehydrogenase inhibitor	Unknown	https://conductscience.org/library/genes/7498

Source Drugs and targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01050907	Miltefosine to Treat Mucocutaneous Leishmaniasis	Phase 2	4	2020-09-30	Mucosal Leishmaniasis, Cutaneous Leishmaniasis	MILTEFOSINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04799236	Treatment of Mucosal Bolivian Leishmaniasis	Phase 3	120		Mucosal Leishmaniasis	AMPHOTERICIN B, ANTIMONY, MILTEFOSINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04699383	Documentation of Patient Outcomes for SSG/Allopurinol Combination Treatment in Ethiopia		105		Cutaneous Leishmaniasis	ALLOPURINOL, SODIUM STIBOGLUCONATE	Its record names the disease	ClinicalTrials.gov
NCT04004754	Outcomes of Complicated CL in Ethiopia Treated With Miltefosine		94		Cutaneous Leishmaniases	MILTEFOSINE	Its record names the disease	ClinicalTrials.gov
NCT01301937	Low Antimonial Dosage in American Mucosal Leishmaniasis	Phase 2/3	76		Mucosal Leishmaniasis, Mucocutaneous Leishmaniasis	MEGLUMINE ANTIMONATE	Its record names the disease	ClinicalTrials.gov
NCT02431429	Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis		55		Mucocutaneous Leishmaniasis	MILTEFOSINE	Its record names the disease	ClinicalTrials.gov
NCT02429518	Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis		42		Mucocutaneous Leishmaniasis	MILTEFOSINE	Its record names the disease	ClinicalTrials.gov
NCT00508963	Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis				Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous	SODIUM STIBOGLUCONATE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37624352	RESULT	1	PubMed
34048461	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005859

GET https://conductscience.org/api/diseases/v1/MONDO_0005859/drugs

API reference For AI assistants